{"id":"NCT05661734","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain","officialTitle":"A Phase 3, Single-arm Study Evaluating the Safety and Effectiveness of VX-548 for Acute Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2023-01-09","primaryCompletion":"2023-12-12","completion":"2023-12-12","firstPosted":"2022-12-22","resultsPosted":"2025-07-01","lastUpdate":"2025-07-01"},"enrollment":258,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pain"],"interventions":[{"type":"DRUG","name":"Suzetrigine","otherNames":["VX-548","SUZ"]}],"arms":[{"label":"Suzetrigine (SUZ)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and effectiveness of VX-548 in treating acute pain.","primaryOutcome":{"measure":"Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","timeFrame":"Day 1 up to Day 30","effectByArm":[{"arm":"Suzetrigine (SUZ)","deltaMin":94,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":14,"countries":["United States"]},"refs":{"pmids":["40165940"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":256},"commonTop":["Headache"]}}